Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years who have been diagnosed with a specific type of lung cancer (non-squamous non-small cell lung cancer) that has spread or cannot be removed with surgery or treated with radiation to cure it, and whose cancer has tested positive for specific gene changes called EGFR mutations (19del or L858R), confirmed through a tissue or blood test.
• People whose cancer has previously been treated with EGFR-targeted therapy (called EGFR-TKI) and has since stopped responding to that treatment, AND who meet one of the following: (a) their cancer progressed after a first- or second-generation EGFR-TKI and a follow-up test confirmed the absence of a specific resistance mutation called T790M; or (b) their cancer progressed after a third-generation EGFR-TKI regardless of T790M status — and in either case, the person has also received platinum-based chemotherapy or was unable to tolerate chemotherapy.
• People who are generally well enough to carry out daily activities with no or minimal limitations, as assessed by a standard medical scale (ECOG score of 0 or 1), and who are expected to live more than 6 months.
• People who are willing and able to provide a stored tumour tissue sample or agree to a new biopsy for research testing.
• People whose blood test results show that their bone marrow, liver, kidney, and clotting functions are within acceptable ranges as defined by the trial.
• People whose heart is pumping at an adequate level (left ventricular ejection fraction of 50% or above).
• People who are able to communicate with the trial team and attend all required visits and follow the trial procedures.

Who may not be able to join:

• People whose lung cancer is of a squamous, mixed, undifferentiated, or small cell type, or those who have previously received systemic cancer treatment (prior surgery-related chemotherapy before or after an operation is generally permitted — confirm with trial site).
• People who currently have brain metastases causing symptoms at the time of joining the trial (people with previously treated brain metastases that have been stable and symptom-free for at least 4 weeks on a steady dose of medication may still be considered — confirm with trial site).
• People who participated in another interventional cancer clinical trial at the same time as their first-line treatment, or within 30 days before starting it.
• People who have had a connection or hole between the airway and oesophagus, a hole in the gut, or an infection inside the abdomen within the 6 months before starting the trial.
• People with serious heart or blood vessel conditions, including stroke, mini-stroke, or heart attack within the past 6 months; significant problems with major blood vessels; unstable chest pain (angina); moderate-to-severe heart failure; or certain abnormal heart rhythm patterns detected on a heart tracing (ECG); or those taking medicines known to affect heart rhythm in a specific way.
• People with uncontrolled health conditions, including: blood sugar that remains very high (poorly controlled diabetes); blood pressure that remains very high despite treatment; or fluid build-up around the lungs, heart, or abdomen that requires drainage more than once a week.
• People who have a history of, or are currently being treated for, a type of lung inflammation called interstitial lung disease or non-infectious pneumonitis, or where this condition cannot be ruled out at screening.
• People with significant existing lung problems, such as a recent blood clot in the lungs (within 3 months), severe asthma, severe chronic obstructive pulmonary disease, restricted lung function, or autoimmune conditions affecting the lungs; or those who have had a lung surgically removed.
• People with active gut conditions such as inflammatory bowel disease, a blocked bowel, severe ulcers, a hole in the gut, an abdominal abscess, or active bleeding in the gut.
• People whose cancer has grown into or is at risk of forming a connection with nearby vital structures such as the heart, oesophagus, or major blood vessels.
• People who still have significant side effects from previous cancer treatments that have not resolved to a mild level (with the exception of hair loss, fatigue, or other effects the doctor considers low risk).
• People who are known to have or are suspected of having an allergy to the study drugs (furmonertinib or sacituzumab tirumotecan) or their ingredients.
• People who are unwilling or unable to use effective contraception during the trial and for 6 months after the last dose of study treatment (this applies to women who could become pregnant and to male participants).
• People with active hepatitis B or hepatitis C infection that meets specific virus level thresholds as defined by the trial.
• People who test positive for HIV or have a history of AIDS, or who have an active syphilis infection.
• People whom the trial doctor considers unsuitable for the trial for other medical or safety reasons.

Important: Always verify eligibility with the trial site directly before applying.